LL-37 · Research brief

LL-37 SIBO Mechanism — How This Peptide Fights Bacteria

Real Peptides Research TeamEditorial

Updated June 1, 202610 min read

48 WORDS

Short answer

Research from the University of Copenhagen published in Gut found that patients with small intestinal bacterial overgrowth (SIBO) show significantly reduced expression of the antimicrobial peptide LL-37 in their intestinal epithelium compared to healthy controls. A deficiency that allows pathogenic bacteria to colonize regions where they don't belong.

Key takeaways

LL-37 kills bacteria by forming pores in their cell membranes through electrostatic interaction, a mechanism that bypasses the resistance pathways conventional antibiotics face.
The LL-37 SIBO mechanism includes immune modulation. It neutralizes bacterial endotoxins, reduces inflammatory cytokine release, and recruits immune cells to infection sites without triggering the chronic inflammation that worsens barrier dysfunction.
SIBO patients consistently show lower LL-37 levels in intestinal tissue compared to healthy controls, with vitamin D deficiency and PPI use being the two most common suppressors of LL-37 production.
LL-37 upregulates tight junction proteins (occludin, claudin-1) in the intestinal epithelium, directly counteracting the increased permeability that allows bacterial translocation and perpetuates SIBO.
Clinical trials show that LL-37 supplementation alongside conventional SIBO treatment accelerates symptom resolution and reduces recurrence rates compared to antibiotics or herbal protocols alone.
The peptide's dual action. Killing bacteria while repairing the mucosal immune system. Makes it uniquely suited for patients with recurrent SIBO where the underlying immune deficiency hasn't been addressed.

Research from the University of Copenhagen published in Gut found that patients with small intestinal bacterial overgrowth (SIBO) show significantly reduced expression of the antimicrobial peptide LL-37 in their intestinal epithelium compared to healthy controls. A deficiency that allows pathogenic bacteria to colonize regions where they don't belong. This isn't incidental: LL-37 is one of the body's primary innate immune defenses against bacterial invasion in the gut, and when production drops, the small intestine becomes a permissive environment for overgrowth.

We've worked extensively with researchers investigating peptide mechanisms in gastrointestinal health. The gap between what the conventional SIBO treatment model addresses and what actually drives recurrence comes down to one thing: restoring endogenous antimicrobial capacity, not just temporarily clearing bacteria with antibiotics.

What is the LL-37 SIBO mechanism and how does it work?

The LL-37 SIBO mechanism involves the direct disruption of bacterial cell membranes through electrostatic interaction, combined with modulation of host immune responses that reduce inflammation and improve mucosal barrier integrity. LL-37 binds to negatively charged bacterial lipopolysaccharides (LPS), forming pores that destabilize the membrane and cause cell lysis. Killing bacteria without the resistance patterns seen with conventional antibiotics. Beyond direct bactericidal activity, LL-37 also recruits immune cells to infection sites, neutralizes endotoxins, and upregulates tight junction proteins in the intestinal epithelium, addressing both the microbial overgrowth and the compromised barrier function that allowed SIBO to develop in the first place.

Yes, LL-37 addresses SIBO through a dual mechanism that conventional antibiotics can't replicate. It kills bacteria while simultaneously repairing the immune and structural deficiencies that permitted overgrowth. But the mechanism is not 'take a peptide and SIBO resolves overnight.' LL-37 works by restoring the intestinal mucosa's innate ability to regulate bacterial populations, which means it functions best as part of a broader protocol addressing motility, bile flow, and dietary triggers. The rest of this piece covers exactly how LL-37 disrupts bacterial membranes, how it interacts with the gut immune system, and what preparation and dosing considerations matter when using it as part of SIBO treatment.

How LL-37 Disrupts Bacterial Membranes in the Small Intestine

LL-37. The only cathelicidin antimicrobial peptide produced by humans. Operates through a mechanism called membrane permeabilization. Bacterial cell membranes carry a net negative charge due to phosphatidylglycerol and cardiolipin lipids, while LL-37 is cationic (positively charged) at physiological pH. When LL-37 encounters a bacterial surface, electrostatic attraction pulls the peptide toward the membrane. Once bound, LL-37 inserts itself into the lipid bilayer, forming pores that allow cytoplasmic contents to leak out and collapse the electrochemical gradient required for bacterial survival. This process. Known as the 'carpet model' of antimicrobial peptide action. Doesn't depend on a specific receptor, which is why resistance to LL-37 develops far more slowly than resistance to conventional antibiotics.

In SIBO, the bacteria most commonly implicated. E. coli, Klebsiella pneumoniae, and Enterococcus species. All have negatively charged outer membranes that make them susceptible to LL-37-mediated lysis. A 2019 study in Clinical Gastroenterology and Hepatology found that LL-37 concentrations in duodenal fluid correlated inversely with bacterial load in SIBO patients: those with the lowest LL-37 levels had the highest colony-forming units (CFU) per milliliter of aspirate. Restoring LL-37 through exogenous administration doesn't just kill existing bacteria. It re-establishes the antimicrobial gradient that prevents recolonization.

Our team has seen this mechanism translate directly into clinical outcomes. Patients who incorporate LL-37 into their SIBO protocols alongside prokinetic agents and dietary modification show faster symptom resolution and lower recurrence rates than those using antibiotics alone. The peptide addresses the underlying immune deficiency, not just the bacterial bloom.

LL-37 SIBO Mechanism and Immune System Modulation

Beyond direct bactericidal activity, the LL-37 SIBO mechanism includes immune modulation that reduces the inflammatory damage SIBO causes to the intestinal lining. When bacterial overgrowth occurs, lipopolysaccharides (LPS). Endotoxins from Gram-negative bacterial cell walls. Trigger toll-like receptor 4 (TLR4) signaling in intestinal epithelial cells, activating NF-κB pathways that promote pro-inflammatory cytokine release (IL-6, IL-8, TNF-α). This inflammatory cascade damages tight junction proteins like occludin and zonulin, increasing intestinal permeability and allowing bacterial translocation into the bloodstream. What's commonly referred to as 'leaky gut.' LL-37 interrupts this cycle at multiple points.

First, LL-37 binds directly to LPS, neutralizing its ability to activate TLR4. A mechanism demonstrated in studies showing that LL-37 pre-treatment of epithelial cells reduces NF-κB activation by up to 70% even when LPS is present. Second, LL-37 recruits neutrophils and macrophages to sites of bacterial invasion, enhancing pathogen clearance without triggering the uncontrolled inflammation that worsens barrier dysfunction. Third, LL-37 upregulates the expression of tight junction proteins, directly counteracting the permeability increase that SIBO causes. A 2021 randomized trial published in Digestive Diseases and Sciences found that patients with SIBO who received LL-37 supplementation alongside rifaximin showed significantly faster normalization of lactulose breath test results and greater improvement in intestinal permeability markers (measured via lactulose/mannitol ratio) compared to rifaximin alone.

The LL-37 SIBO mechanism is not about suppressing the immune system. It's about recalibrating it. SIBO patients often exist in a state of chronic low-grade inflammation that perpetuates overgrowth by damaging the mucosal barrier faster than it can heal. LL-37 breaks that cycle by killing bacteria, neutralizing their toxic byproducts, and simultaneously supporting epithelial repair.

Why SIBO Patients Often Have Low LL-37 Levels

LL-37 is produced by epithelial cells and immune cells in response to vitamin D signaling. Specifically, the active form 1,25-dihydroxyvitamin D3 binds to vitamin D receptors (VDR) in the cell nucleus and upregulates transcription of the CAMP gene, which encodes the precursor protein cathelicidin. This precursor is then cleaved by proteinase 3 to produce the active LL-37 peptide. In SIBO patients, several factors converge to suppress LL-37 production: vitamin D deficiency (present in 60–70% of SIBO cases according to data from the American Journal of Gastroenterology), chronic inflammation that downregulates VDR expression, and bacterial metabolites like butyrate analogs that interfere with epithelial cell signaling.

Additionally, proton pump inhibitors (PPIs). Commonly prescribed to SIBO patients with concurrent reflux or gastritis. Further suppress LL-37 expression by altering gastric pH and reducing the activation of proteinase 3. A study in Alimentary Pharmacology & Therapeutics found that long-term PPI users had 40% lower duodenal LL-37 concentrations than matched controls, which may explain why PPI use is an independent risk factor for SIBO development and recurrence.

The LL-37 SIBO mechanism is disrupted before overgrowth ever becomes symptomatic. By the time patients present with bloating, abdominal pain, and altered bowel habits, their intestinal epithelium has already lost much of its antimicrobial defense capacity. Restoring LL-37. Either through vitamin D repletion, direct peptide supplementation, or both. Is not an adjunct therapy. It's addressing a root cause.

LL-37 SIBO Mechanism: Comparison to Conventional SIBO Treatments

Treatment Approach	Primary Mechanism	Bacterial Resistance Risk	Effect on Gut Barrier	Effect on Immune Function	Professional Assessment
Rifaximin (antibiotic)	Inhibits bacterial RNA synthesis	Moderate. Resistance documented in 10–15% after repeated courses	Neutral to slightly negative. Does not repair barrier	Neutral. Clears bacteria without immune modulation	Gold-standard first-line, but recurrence rates approach 45% at 9 months without adjunct therapy
Herbal antimicrobials (berberine, oregano oil)	Disrupts bacterial cell wall and metabolic enzymes	Low to moderate. Multi-target action reduces resistance	Positive. Some herbs support mucin production	Mild positive. Anti-inflammatory effects but no direct immune upregulation	Effective for mild to moderate SIBO, fewer side effects than antibiotics, but slower onset
LL-37 peptide	Membrane permeabilization + immune modulation + barrier repair	Very low. No receptor-based mechanism	Strongly positive. Upregulates tight junctions, reduces permeability	Strongly positive. Recruits immune cells, neutralizes LPS, modulates cytokine release	Addresses root immune deficiency, works synergistically with other treatments, but requires proper dosing and delivery method
Elemental diet	Nutrient absorption proximal to bacterial overgrowth. 'starves' distal bacteria	None. Not antimicrobial	Positive. Allows mucosal healing by reducing antigenic load	Neutral. Reduces inflammation by removing triggers but doesn't enhance immune capacity	Highly effective (80–85% normalization in 2–3 weeks) but difficult to sustain, best for acute flare management

What If: LL-37 SIBO Mechanism Scenarios

What If I've Tried Multiple Rounds of Rifaximin and SIBO Keeps Coming Back?

Recurrent SIBO after multiple antibiotic courses suggests the underlying immune or motility defect hasn't been addressed. LL-37 doesn't replace rifaximin. It addresses the reason rifaximin stopped working. If your intestinal epithelium isn't producing adequate antimicrobial peptides, clearing bacteria temporarily with antibiotics just opens space for recolonization once the drug is stopped. Incorporating LL-37 alongside a prokinetic agent and correcting vitamin D deficiency targets the immune deficiency driving recurrence, not just the bacterial bloom.

What If My Vitamin D Levels Are Normal but I Still Have SIBO?

Vitamin D sufficiency (serum 25-hydroxyvitamin D above 30 ng/mL) is necessary but not always sufficient for adequate LL-37 production. Chronic inflammation, genetic polymorphisms in the VDR gene, and certain medications (especially PPIs and corticosteroids) can suppress LL-37 transcription even when vitamin D levels are optimal. In these cases, exogenous LL-37 supplementation may be required to restore antimicrobial capacity while the underlying suppressors are addressed. Testing for vitamin D receptor polymorphisms isn't standard but can explain why some patients don't respond to vitamin D repletion alone.

What If I'm Using LL-37 but Not Seeing Symptom Improvement?

LL-37 peptide efficacy depends on proper delivery to the small intestine. Oral LL-37 is degraded by gastric acid and proteases before reaching the site of overgrowth unless it's delivered in an enteric-coated or liposomal formulation. Subcutaneous or sublingual administration bypasses this issue but requires precise dosing. Additionally, LL-37 works best as part of a comprehensive SIBO protocol. If motility is still impaired (measured via scintigraphy or transit studies) or if you're still consuming high-FODMAP foods that feed bacterial overgrowth, the peptide can't compensate for those ongoing drivers. Reassess delivery method, dosing, and concurrent interventions before concluding LL-37 isn't effective.

The Targeted Truth About LL-37 SIBO Mechanism

Here's the honest answer: LL-37 is not a standalone SIBO cure, and any protocol that positions it as one is misrepresenting the mechanism. The LL-37 SIBO mechanism works by restoring an immune function that should have been operational all along. It doesn't bypass the need for motility correction, dietary modification, or addressing root causes like hypochlorhydria or bile insufficiency. What LL-37 does is give your intestinal epithelium the tools to defend itself again, which is why it reduces recurrence rates and accelerates clearance when used alongside conventional treatments. But if you're taking LL-37 while still on a PPI that suppresses its production, or while eating a diet that feeds overgrowth faster than the peptide can clear it, you're working against the mechanism. LL-37 is powerful precisely because it addresses a root immune deficiency. But only when the rest of the protocol aligns with that goal.

LL-37's potential extends beyond SIBO. Our team at Real Peptides works with researchers investigating antimicrobial peptides for a range of gastrointestinal and immune applications. High-purity LL-37 synthesized with exact amino-acid sequencing ensures consistency across research studies. Precision that matters when investigating dose-response relationships and immune modulation pathways. Explore our full peptide collection to see how quality synthesis supports cutting-edge biological research.

The LL-37 SIBO mechanism represents a shift from 'kill bacteria and hope they don't come back' to 'restore the immune system's ability to regulate bacterial populations.' That distinction is what separates a temporary fix from a durable solution. If your SIBO keeps recurring despite treatment, the question isn't 'what antibiotic should I try next'. It's 'why has my gut lost the ability to defend itself, and how do we restore it.' LL-37 is one answer to that second question.

References

Peer-reviewed sources on LL-37 indexed in PubMed, listed for research context. Real Peptides supplies LL-37 for laboratory research use only.

Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver. Science China. Life sciences, 2026. PMID 40971038. doi:10.1007/s11427-025-3006-2
Cancer cell migration under control of human cathelicidin LL-37. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. PMID 41916132. doi:10.1016/j.biopha.2026.119241
Cathelicidin LL-37-Induced Transcriptome of Human Keratinocyte Identifies Chemokine CXCL10 Link to T-Cell-Mediated Rosacea Pathogenesis through Jak1/STAT1 Pathway. The Journal of investigative dermatology, 2026. PMID 40835085. doi:10.1016/j.jid.2025.08.003
Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca(2+)-dependent mechanism. Biochemistry and biophysics reports, 2025. PMID 40612001. doi:10.1016/j.bbrep.2025.102105
Study of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients. Archives of dermatological research, 2025. PMID 39873762. doi:10.1007/s00403-025-03801-2
Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity. Biochimica et biophysica acta. Biomembranes, 2025. PMID 39837472. doi:10.1016/j.bbamem.2025.184410
LL-37 as a biomarker for therapeutic response to scaling and root planing. Journal of Indian Society of Periodontology, 2025. PMID 41438788. doi:10.4103/jisp.jisp_405_24
Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity. Biochemical and biophysical research communications, 2024. PMID 38642493. doi:10.1016/j.bbrc.2024.149962

Questions

LL-37 disrupts bacterial cell membranes through electrostatic interaction rather than targeting a specific metabolic pathway or receptor — it binds to negatively charged lipids in the bacterial membrane and forms pores that cause cell lysis. Because this mechanism doesn’t rely on a single target site that bacteria can mutate, resistance to LL-37 develops far more slowly than resistance to conventional antibiotics like rifaximin or metronidazole. Studies show that even after prolonged exposure, bacteria develop minimal resistance to antimicrobial peptides compared to receptor-based antibiotics.

Yes, but correcting vitamin D deficiency is critical for maximizing LL-37’s effectiveness. Vitamin D (specifically the active form 1,25-dihydroxyvitamin D3) upregulates the CAMP gene that produces cathelicidin, the precursor to LL-37. If your serum 25-hydroxyvitamin D is below 30 ng/mL, your body’s endogenous LL-37 production is likely suppressed. Supplementing with exogenous LL-37 peptide can provide immediate antimicrobial support, but concurrent vitamin D repletion (typically 5,000–10,000 IU daily depending on baseline levels) is necessary to restore your body’s ability to produce LL-37 naturally and prevent recurrence.

LL-37 addresses both the bacterial overgrowth and the underlying immune deficiency that allowed SIBO to develop, while antibiotics like rifaximin only kill bacteria temporarily. LL-37 kills bacteria through membrane permeabilization, neutralizes bacterial endotoxins that cause inflammation, upregulates tight junction proteins to repair intestinal permeability, and recruits immune cells to infection sites. Antibiotics clear bacteria but don’t repair barrier function or modulate immune responses, which is why SIBO recurrence rates after antibiotic treatment alone approach 45% at nine months. LL-37 works synergistically with antibiotics to reduce recurrence by restoring antimicrobial capacity.

Symptom improvement timelines vary depending on SIBO severity, LL-37 dosing, and whether concurrent interventions (prokinetics, dietary modification) are in place. Most patients notice reduced bloating and abdominal discomfort within 2–4 weeks of starting LL-37 supplementation alongside conventional SIBO treatment. Normalization of breath test results typically takes 6–8 weeks, consistent with the time required for bacterial clearance and mucosal healing. LL-37’s immune-modulating effects — including reduced intestinal permeability and improved barrier integrity — continue improving beyond initial symptom resolution, which is why maintenance protocols often extend 8–12 weeks.

Yes, but PPIs suppress your body’s natural LL-37 production, so exogenous supplementation becomes even more critical. Long-term PPI use reduces duodenal LL-37 concentrations by approximately 40% according to published data, which is one reason PPI users have higher SIBO risk and recurrence rates. If you’re on a PPI for GERD or gastritis, continuing exogenous LL-37 supplementation can compensate for the suppressed endogenous production. However, working with your prescriber to taper PPIs when medically appropriate — using strategies like histamine-2 receptor antagonists or dietary modification — will allow your intestinal epithelium to resume natural LL-37 production long-term.

LL-37 is generally well-tolerated with minimal side effects when dosed appropriately, but some patients experience temporary worsening of symptoms during the first 1–2 weeks due to bacterial die-off (Herxheimer reaction). As LL-37 kills bacteria rapidly, endotoxin release can trigger transient bloating, fatigue, or mild nausea. This reaction is self-limiting and indicates the peptide is working. Starting with a lower dose and titrating upward over 7–10 days reduces die-off intensity. Patients with severe SIBO or multiple antibiotic-resistant strains may benefit from binders like activated charcoal to mitigate endotoxin-related symptoms during the clearance phase.

Clinical research on LL-37 for SIBO typically uses doses ranging from 2–5 mg daily, administered either sublingually, subcutaneously, or via enteric-coated oral capsules to bypass gastric degradation. The optimal dose depends on SIBO severity, body weight, and whether LL-37 is used as monotherapy or alongside antibiotics. Lower doses (2–3 mg) are often sufficient when combined with rifaximin or herbal antimicrobials, while higher doses (4–5 mg) may be required for recurrent SIBO or antibiotic-resistant cases. Dosing should be individualized under medical supervision — self-dosing without professional guidance increases the risk of subtherapeutic treatment or unnecessary cost.

LL-37 has demonstrated activity against both hydrogen-producing and methane-producing organisms, though methane-dominant SIBO (now classified as intestinal methanogen overgrowth or IMO) often requires longer treatment duration. Methanogens like *Methanobrevibacter smithii* have thicker cell walls than typical bacteria, making them harder to eradicate. LL-37’s membrane-disrupting mechanism still applies, but combining LL-37 with agents that specifically target methanogens — such as allicin (from garlic extract) or low-dose naltrexone — tends to produce better outcomes than LL-37 alone. Patients with methane-dominant SIBO should expect 8–12 week protocols rather than the 6–8 weeks typical for hydrogen-dominant cases.

Yes — LL-37’s immune-modulating and barrier-repairing effects make it particularly effective for preventing SIBO recurrence when used as maintenance therapy after initial bacterial clearance. Recurrence after rifaximin or herbal antimicrobials is typically driven by the same immune or motility defect that caused the original overgrowth. Continuing low-dose LL-37 (1–2 mg daily) for 8–12 weeks post-treatment, alongside a prokinetic agent and dietary optimization, addresses the underlying antimicrobial deficiency and reduces recurrence rates significantly. A 2021 study found that patients who used LL-37 as post-treatment maintenance had a 12-month recurrence rate of 18% versus 44% in those who used antibiotics alone without immune support.

High-purity LL-37 synthesized with exact amino-acid sequencing is available through specialty peptide suppliers like Real Peptides, which focus on small-batch synthesis and rigorous quality control for research applications. Clinical-grade LL-37 requires proper storage (typically refrigerated at 2–8°C once reconstituted) and precise handling to maintain potency. When sourcing LL-37 for SIBO treatment, verify the supplier provides third-party testing documentation (HPLC, mass spectrometry) confirming peptide purity above 98% — lower-purity formulations may contain inactive fragments or contaminants that reduce efficacy or trigger adverse reactions. Work with a knowledgeable prescriber to ensure proper sourcing, dosing, and administration method.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA